203 related articles for article (PubMed ID: 20176911)
1. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Morrow BJ; He W; Amsler KM; Foleno BD; Macielag MJ; Lynch AS; Bush K
Antimicrob Agents Chemother; 2010 May; 54(5):1955-64. PubMed ID: 20176911
[TBL] [Abstract][Full Text] [Related]
2. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
Morrow BJ; Abbanat D; Baum EZ; Crespo-Carbone SM; Davies TA; He W; Shang W; Queenan AM; Lynch AS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5512-21. PubMed ID: 21911562
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.
Fernandez J; Hilliard JJ; Morrow BJ; Melton JL; Flamm RK; Barron AM; Lynch AS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5522-8. PubMed ID: 21911568
[TBL] [Abstract][Full Text] [Related]
4. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Farrell DJ; Liverman LC; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 2011 Jul; 55(7):3631-4. PubMed ID: 21555765
[TBL] [Abstract][Full Text] [Related]
5. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
6. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains.
Biedenbach DJ; Turner LL; Jones RN; Farrell DJ
Diagn Microbiol Infect Dis; 2012 Oct; 74(2):204-6. PubMed ID: 22819604
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
Farrell DJ; Liverman LC; Biedenbach DJ; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):415-20. PubMed ID: 21982563
[TBL] [Abstract][Full Text] [Related]
8. Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Jones TM; Johnson SW; DiMondi VP; Wilson DT
Infect Drug Resist; 2016; 9():119-28. PubMed ID: 27354817
[TBL] [Abstract][Full Text] [Related]
9. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
11. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
12. Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.
Eichenbaum G; Pugsley MK; Gallacher DJ; Towart R; McIntyre G; Shukla U; Davenport JM; Lu HR; Rohrbacher J; Hillsamer V
Br J Pharmacol; 2012 Jul; 166(5):1694-707. PubMed ID: 22289150
[TBL] [Abstract][Full Text] [Related]
13. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
15.
Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
Zhang Y; Li G; Liu M; You X; Feng L; Lv K; Cao J; Guo H
Bioorg Med Chem Lett; 2011 Feb; 21(3):928-31. PubMed ID: 21232952
[TBL] [Abstract][Full Text] [Related]
18. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
Zhang FF; Zhao CJ; Wang H
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin Derivatives with Potential Antibacterial Activity against Methicillin- Resistant Staphylococcus Aureus (MRSA).
Chen R; Xue H; Xu Y; Ma T; Liu Y; Zhang J; Shi X; Guo D
Curr Top Med Chem; 2021; 21(27):2474-2482. PubMed ID: 34645377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
